Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gamezumab Safety and PK for Ebola Prevention
NCT04717830Phase 1Unknown
- Start
- Feb 2021
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of GamEMab in Ebola virus disease (EVD) (3 arms). Primary endpoints: Number of Participants With Serious Adverse Events at 90 days, Number of Participants with Solicited Local and Systemic Adverse Events at 90 days and 1 more. Status: unknown.
02
Drugs
GamEMab
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT04717830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04717830.